![]() ![]() However, more recent reports 3, 4 have shown that 3-month (3-mo) duration of DAPT could reduce hemorrhagic risk without increasing the risk of ischemic events. Unique identifier: NCT02494895.Ĭurrent guidelines 1, 2 recommend 12-month (12-mo) dual antiplatelet therapy (DAPT) consisting of aspirin with a P2Y 12 inhibitor after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). A higher bleeding tendency in 12-mo DAPT compared with 3-mo DAPT was more obvious in the pre-TIMI 2/3 group than in the pre-TIMI 0/1 group.Ĭlinical Trial Registration: URL. The occurrence of MACCE was similar between the two groups. However, in the pre-TIMI 2/3 group, the occurrences of TIMI minor (adjusted hazard ratio : 0.294 p = 0.016) and major or minor bleeding (aHR: 0.483 p = 0.014) on intention-to-treat analysis were significantly higher in the 12-mo than in the 3-mo DAPT group. In the pre-TIMI 0/1 group, the primary and second outcomes were not significantly different between the 3-mo and 12-mo DAPT groups. The secondary outcomes were the occurrence of the individual components of TIMI bleedings and MACCE. The primary outcome was the occurrence of net adverse clinical events (NACE), defined as a composite of TIMI major bleeding and major adverse cardiac and cerebrovascular events (MACCE) within 12-mo following PCI. This was a post hoc analysis of the TICO trial. We investigated the impact of pre-percutaneous coronary intervention (pre-PCI) thrombolysis in myocardial infarction (TIMI) flow grade (pre-TIMI) on 3-month (3-mo) and 12-mo of dual antiplatelet therapy (DAPT) in patients with acute myocardial infarction (AMI). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |